Lucid Historical Balance Sheet

LUCD Stock  USD 0.79  0.02  2.60%   
Trend analysis of Lucid Diagnostics balance sheet accounts such as Accounts Payable of 1.3 M provides information on Lucid Diagnostics' total assets, liabilities, and equity, which is the actual value of Lucid Diagnostics to its prevalent stockholders. By breaking down trends over time using Lucid Diagnostics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Lucid Diagnostics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lucid Diagnostics is a good buy for the upcoming year.

Lucid Diagnostics Inventory

274,520

  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

About Lucid Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lucid Diagnostics at a specified time, usually calculated after every quarter, six months, or one year. Lucid Diagnostics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lucid Diagnostics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lucid currently owns. An asset can also be divided into two categories, current and non-current.

Lucid Diagnostics Balance Sheet Chart

At present, Lucid Diagnostics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 1.3 M, whereas Total Current Assets are forecasted to decline to about 19.4 M.

Accounts Payable

An accounting item on the balance sheet that represents Lucid Diagnostics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lucid Diagnostics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most accounts from Lucid Diagnostics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.At present, Lucid Diagnostics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 1.3 M, whereas Total Current Assets are forecasted to decline to about 19.4 M.
 2023 2024 (projected)
Other Liabilities324.4K288.3K
Total Current Liabilities29.4M30.9M

Lucid Diagnostics balance sheet Correlations

-0.870.6-0.890.650.370.670.440.78-0.01-0.030.370.570.79-0.720.370.830.78-0.070.660.910.98-0.10.91-0.10.24
-0.87-0.680.82-0.33-0.28-0.48-0.36-0.480.06-0.05-0.31-0.41-0.60.84-0.31-0.87-0.720.1-0.51-0.95-0.910.15-0.950.14-0.21
0.6-0.68-0.74-0.08-0.030.450.090.41-0.240.31-0.010.710.73-0.49-0.010.760.59-0.550.280.710.69-0.30.71-0.35-0.27
-0.890.82-0.74-0.5-0.58-0.88-0.66-0.54-0.270.26-0.58-0.83-0.940.58-0.58-0.73-0.96-0.06-0.82-0.88-0.87-0.18-0.88-0.16-0.37
0.65-0.33-0.08-0.50.560.580.570.620.34-0.450.550.360.51-0.110.550.160.520.380.60.340.520.310.330.30.5
0.37-0.28-0.03-0.580.560.820.99-0.050.92-0.931.00.530.52-0.081.0-0.010.770.830.920.310.240.880.310.880.94
0.67-0.480.45-0.880.580.820.880.330.63-0.620.810.880.9-0.230.810.360.940.390.940.580.570.570.580.540.61
0.44-0.360.09-0.660.570.990.880.00.89-0.890.990.620.61-0.120.990.070.840.760.940.380.320.840.380.840.9
0.78-0.480.41-0.540.62-0.050.330.0-0.390.31-0.070.330.58-0.48-0.070.680.34-0.360.270.60.79-0.440.6-0.45-0.17
-0.010.06-0.24-0.270.340.920.630.89-0.39-0.990.920.390.270.260.92-0.380.530.890.7-0.06-0.151.0-0.060.990.89
-0.03-0.050.310.26-0.45-0.93-0.62-0.890.31-0.99-0.93-0.33-0.25-0.23-0.930.37-0.51-0.93-0.720.050.11-0.980.05-0.99-0.92
0.37-0.31-0.01-0.580.551.00.810.99-0.070.92-0.930.520.51-0.11.00.00.780.830.910.330.250.880.320.880.95
0.57-0.410.71-0.830.360.530.880.620.330.39-0.330.520.94-0.070.520.350.840.00.690.490.520.340.490.280.22
0.79-0.60.73-0.940.510.520.90.610.580.27-0.250.510.94-0.330.510.580.9-0.020.770.70.750.20.70.160.25
-0.720.84-0.490.58-0.11-0.08-0.23-0.12-0.480.26-0.23-0.1-0.07-0.33-0.1-0.91-0.440.13-0.36-0.89-0.80.34-0.90.3-0.13
0.37-0.31-0.01-0.580.551.00.810.99-0.070.92-0.931.00.520.51-0.10.00.780.830.910.330.250.880.320.880.95
0.83-0.870.76-0.730.16-0.010.360.070.68-0.380.370.00.350.58-0.910.00.54-0.390.350.940.92-0.460.94-0.45-0.1
0.78-0.720.59-0.960.520.770.940.840.340.53-0.510.780.840.9-0.440.780.540.310.920.760.720.450.760.430.58
-0.070.1-0.55-0.060.380.830.390.76-0.360.89-0.930.830.0-0.020.130.83-0.390.310.59-0.1-0.190.89-0.10.920.94
0.66-0.510.28-0.820.60.920.940.940.270.7-0.720.910.690.77-0.360.910.350.920.590.620.560.640.610.640.8
0.91-0.950.71-0.880.340.310.580.380.6-0.060.050.330.490.7-0.890.330.940.76-0.10.620.95-0.151.0-0.140.22
0.98-0.910.69-0.870.520.240.570.320.79-0.150.110.250.520.75-0.80.250.920.72-0.190.560.95-0.240.95-0.240.12
-0.10.15-0.3-0.180.310.880.570.84-0.441.0-0.980.880.340.20.340.88-0.460.450.890.64-0.15-0.24-0.161.00.86
0.91-0.950.71-0.880.330.310.580.380.6-0.060.050.320.490.7-0.90.320.940.76-0.10.611.00.95-0.16-0.140.22
-0.10.14-0.35-0.160.30.880.540.84-0.450.99-0.990.880.280.160.30.88-0.450.430.920.64-0.14-0.241.0-0.140.89
0.24-0.21-0.27-0.370.50.940.610.9-0.170.89-0.920.950.220.25-0.130.95-0.10.580.940.80.220.120.860.220.89
Click cells to compare fundamentals

Lucid Diagnostics Account Relationship Matchups

Lucid Diagnostics balance sheet Accounts

201920202021202220232024 (projected)
Total Current Liabilities6.3M15.7M4.3M8.4M29.4M30.9M
Net Tangible Assets(5.3M)(13.5M)(24.1M)19.6M22.5M23.7M
Retained Earnings(5.5M)(13.8M)(41.9M)(98.1M)(150.7M)(143.2M)
Accounts Payable799.1K2.1M1.5M1.1M1.1M1.3M
Total Current Assets390.9K1.4M57.3M24.4M22.1M19.4M
Common Stock14.1K14.1K35K41K42K28.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.09
Quarterly Revenue Growth
0.497
Return On Assets
(1.01)
Return On Equity
(10.08)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.